Molecular Characterization of Candida Auris (OC)

Formulation Development and In-Vitro Studies of Efficacy of Botanical Extracts Against Candida Auris

Candida auris is emerging fungal opportunistic pathogen in developing countries. Much studies has been conducted on Candida albicans. there was a dire need to investigate this alarming threat. Our hypothesis is that by recording the patients diagnosed with oropharygneal candidiasis and collecting clinical swab samples from these patients will be fruitful if microbiological isolation, identification and molecular characterization will be done. So this is the first study on C. auris in south punjab, Pakistan. Aim of this study is to collect epidemiological data of C. auris.

Study Overview

• Status: Completed
• Conditions: Oral Fungal Infection
• Intervention / Treatment: Other: No intervention

• Study Type: Observational
• Enrollment (Actual): 384

Contacts and Locations

Study Locations

• Pakistan
  • Punjab
    • Bahawalpur, Punjab, Pakistan, 63100
      • Bahawal Victoria Hospital Bahawalpur
    • Bahawalpur, Punjab, Pakistan, 63100
      • Civil Hospital Jhangi Wala Road Bahawalpur

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 100 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

All individuals are equally eligible to be selected in the study

Description

Inclusion Criteria:

• Pre-diagnosed Patients of both gender from pre-selected localities

Exclusion Criteria:

• Healthy individuals or individuals having no oral fungal infection individuals above 100 years of age

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of C. auris	patients from selected localities will be recorded along with total patients in that category, prevalence will be calculated on the record collected from specified duration of study	From November 15, 2019 to February 29, 2020
Seasonality of C. auris infection	Number of patients recorded during different months will be the source of calculation of seasonality index of the C. auris infection	From November 15, 2019 to February 29, 2020
Drug susceptibility	Antifungal drug discs will be used for assessing the antfungal drugs susceptibility	From November 15, 2019 to February 29, 2020

Collaborators and Investigators

• Sponsor: Islamia University of Bahawalpur
• Investigators: Principal Investigator: Jafi H Shirazi, M.Phil, The Islamia University of Bahawalpur

Study record dates

Study Major Dates

• Study Start (Actual): November 15, 2019
• Primary Completion (Actual): February 29, 2020
• Study Completion (Actual): February 29, 2020

Study Registration Dates

• First Submitted: October 7, 2019
• First Submitted That Met QC Criteria: October 9, 2019
• First Posted (Actual): October 10, 2019

Study Record Updates

• Last Update Posted (Actual): October 27, 2020
• Last Update Submitted That Met QC Criteria: October 25, 2020
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Keywords: Candida auris; Oral Fungal Infection; Candidiasis
• Additional Relevant MeSH Terms: Infections; Bacterial Infections and Mycoses; Mycoses
• Other Study ID Numbers: Oral Fungal Infection

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: Individual privacy is prime important, hence data will not be shared

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No